176 related articles for article (PubMed ID: 9385477)
1. Managing side effects of interferon-beta in patients with relapsing-remitting multiple sclerosis.
Munschauer FE; Kinkel RP
Clin Ther; 1997; 19(5):883-93. PubMed ID: 9385477
[TBL] [Abstract][Full Text] [Related]
2. A meta-analysis of the efficacy and tolerability of interferon-β in multiple sclerosis, overall and by drug and disease type.
Nikfar S; Rahimi R; Abdollahi M
Clin Ther; 2010 Oct; 32(11):1871-88. PubMed ID: 21095482
[TBL] [Abstract][Full Text] [Related]
3. Interferon beta for multiple sclerosis.
Connelly JF
Ann Pharmacother; 1994 May; 28(5):610-6. PubMed ID: 8069001
[TBL] [Abstract][Full Text] [Related]
4. Side effect profile of interferon beta-1b in MS: results of an open label trial.
Neilley LK; Goodin DS; Goodkin DE; Hauser SL
Neurology; 1996 Feb; 46(2):552-4. PubMed ID: 8614531
[TBL] [Abstract][Full Text] [Related]
5. A randomized open label study of pain medications (naproxen, acetaminophen and ibuprofen) for controlling side effects during initiation of IFN beta-1a therapy and during its ongoing use for relapsing-remitting multiple sclerosis.
Leuschen MP; Filipi M; Healey K
Mult Scler; 2004 Dec; 10(6):636-42. PubMed ID: 15584488
[TBL] [Abstract][Full Text] [Related]
6. Interferon beta treatment for multiple sclerosis: persisting questions.
Goodkin DE
Mult Scler; 1996 Jul; 1(6):321-4. PubMed ID: 9345408
[TBL] [Abstract][Full Text] [Related]
7. Amelioration of flulike symptoms at the onset of interferon beta-1b therapy in multiple sclerosis by low-dose oral steroids is related to a decrease in interleukin-6 induction.
Martínez-Cáceres EM; Río J; Barrau M; Durán I; Borrás C; Tintoré M; Montalban X
Ann Neurol; 1998 Oct; 44(4):682-5. PubMed ID: 9778268
[TBL] [Abstract][Full Text] [Related]
8. Autoantibodies in multiple sclerosis patients before and during IFN-beta 1b treatment: are they correlated with the occurrence of autoimmune diseases?
Verdun E; Isoardo G; Oggero A; Ferrero B; Ghezzi A; Montanari E; Zaffaroni M; Durelli L;
J Interferon Cytokine Res; 2002 Feb; 22(2):245-55. PubMed ID: 11911808
[TBL] [Abstract][Full Text] [Related]
9. Development of interferon-beta as a therapy for multiple sclerosis.
Markowitz C
Expert Opin Emerg Drugs; 2004 Nov; 9(2):363-74. PubMed ID: 15571491
[TBL] [Abstract][Full Text] [Related]
10. Acute delirium, delusion, and depression during IFN-beta-1a therapy for multiple sclerosis: a case report.
Goëb JL; Cailleau A; Lainé P; Etcharry-Bouyx F; Maugin D; Duverger P; Gohier B; Rannou-Dubas K; Dubas F; Garré JB
Clin Neuropharmacol; 2003; 26(1):5-7. PubMed ID: 12567157
[TBL] [Abstract][Full Text] [Related]
11. Blood levels of transforming growth factor-beta 1 (TGF-beta1) are elevated in both relapsing remitting and chronic progressive multiple sclerosis (MS) patients and are further augmented by treatment with interferon-beta 1b (IFN-beta1b).
Nicoletti F; Di Marco R; Patti F; Reggio E; Nicoletti A; Zaccone P; Stivala F; Meroni PL; Reggio A
Clin Exp Immunol; 1998 Jul; 113(1):96-9. PubMed ID: 9697990
[TBL] [Abstract][Full Text] [Related]
12. Every-other-day interferon beta-1b versus once-weekly interferon beta-1a for multiple sclerosis: results of a 2-year prospective randomised multicentre study (INCOMIN).
Durelli L; Verdun E; Barbero P; Bergui M; Versino E; Ghezzi A; Montanari E; Zaffaroni M;
Lancet; 2002 Apr; 359(9316):1453-60. PubMed ID: 11988242
[TBL] [Abstract][Full Text] [Related]
13. Further study on the specificity and incidence of neutralizing antibodies to interferon (IFN) in relapsing remitting multiple sclerosis patients treated with IFN beta-1a or IFN beta-1b.
Antonelli G; Simeoni E; Bagnato F; Pozzilli C; Turriziani O; Tesoro R; Di Marco P; Gasperini C; Fieschi C; Dianzani F
J Neurol Sci; 1999 Oct; 168(2):131-6. PubMed ID: 10526196
[TBL] [Abstract][Full Text] [Related]
14. Management of patients receiving interferon beta-1b for multiple sclerosis: report of a consensus conference.
Lublin FD; Whitaker JN; Eidelman BH; Miller AE; Arnason BG; Burks JS
Neurology; 1996 Jan; 46(1):12-8. PubMed ID: 8559358
[TBL] [Abstract][Full Text] [Related]
15. Newer versus older treatments for relapsing-remitting multiple sclerosis.
Weinstock-Guttman B; Cohen JA
Drug Saf; 1996 Feb; 14(2):121-30. PubMed ID: 8852526
[TBL] [Abstract][Full Text] [Related]
16. Interferon-beta 1b treatment decreases tumor necrosis factor-alpha and increases interleukin-6 production in multiple sclerosis.
Brod SA; Marshall GD; Henninger EM; Sriram S; Khan M; Wolinsky JS
Neurology; 1996 Jun; 46(6):1633-8. PubMed ID: 8649562
[TBL] [Abstract][Full Text] [Related]
17. Interferon-beta-1b: a review of its use in relapsing-remitting and secondary progressive multiple sclerosis.
McCormack PL; Scott LJ
CNS Drugs; 2004; 18(8):521-46. PubMed ID: 15182221
[TBL] [Abstract][Full Text] [Related]
18. Delayed occurrence of a severe cutaneous reaction in a multiple sclerosis patient taking interferon beta-1b.
Cohen BA; Greenberger PA; Saini S
Allergy Asthma Proc; 1998; 19(2):85-8. PubMed ID: 9578917
[TBL] [Abstract][Full Text] [Related]
19. Autoimmune hyperthyroidism in patients with multiple sclerosis treated with interferon beta-1b.
Schwid SR; Goodman AD; Mattson DH
Arch Neurol; 1997 Sep; 54(9):1169-90. PubMed ID: 9311363
[TBL] [Abstract][Full Text] [Related]
20. What is new in the treatment of multiple sclerosis?
Weinstock-Guttman B; Jacobs LD
Drugs; 2000 Mar; 59(3):401-10. PubMed ID: 10776827
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
